Effects of kuntai capsule in combination with hormone replacement therapy on premature ovarian failure and bone metabolism

This study evaluates the clinical effectiveness of combining kuntai capsule with hormone replacement therapy (HRT) in treating premature ovarian failure (POF) and its impact on ovarian reserve and bone metabolism. A total of 190 POF patients were randomly assigned to either a control group (n=95) receiving HRT alone (1 mg estradiol valerate tablets and 10 mg dydrogesterone tablets), or an observation group (n=95) receiving a combination of HRT and Kuntai Capsule. After three months of treatment, the observation group showed significantly better ovarian reserve, with a higher overall effective rate (87.37% vs. 71.58%). Hormonal analysis revealed lower follicle-stimulating hormone (FSH) and luteinizing hormone (LH) levels, and higher estradiol (E2) levels in the observation group compared to the control. Furthermore, ovarian reserve markers such as anti-Müllerian hormone (AMH) and antral follicle count were also higher in the observation group. Bone metabolism improvements were noted, with higher osteocalcin (OST) and lower bone-specific alkaline phosphatase (BAP) levels. The observation group also had a significantly lower recurrence rate (7.3%) after 24 months, compared to the control group (16.8%). These results suggest that the combination of Kuntai Capsule and HRT offers a promising treatment for POF, improving ovarian function, hormone levels, and bone health while reducing recurrence risk.